If you’ve had a COVID-19 vaccine, you’ve already been on the receiving end of one of the more remarkable innovations in modern medicine: a lipid nanoparticle, or LNP. These tiny fat-based spheres are essentially molecular couriers — they carry fragile mRNA instructions into your cells without them falling apart en route. The Pfizer-BioNTech and Moderna vaccines relied on them entirely. Without LNPs, there’s no shot.
So what happens when researchers try to make them better?
According to a February 2024 paper in Nature Communications from the University of Pennsylvania, the answer — at least in part — involves thinking about space shuttles.
The Problem with Getting mRNA Where It Needs to Go
LNPs are built from several components, but one of the most critical is something called an ionisable lipidoid. This is the molecule that helps the nanoparticle fuse with a cell membrane and release its cargo inside. Get the lipidoid wrong and the whole delivery system underperforms.
Scientists already knew that lipidoids with branched, tree-like “tails” tended to work better than simpler, straight-chained versions. The branching seems to improve how well the particle can sneak into cells and unload its payload. The catch? Making those branched lipidoids was slow, expensive, and technically fiddly.
Penn Engineering’s Mitchell Lab set out to fix that.
A Rocket Analogy That Actually Holds Up
The new synthesis method was conceived by postdoctoral researcher Xuexiang Han, who — inspired by a childhood documentary about NASA’s space shuttle — noticed a structural parallel between the shuttle-and-boosters design and the architecture of a well-performing lipidoid.
A space shuttle doesn’t reach orbit on its own. It’s strapped to solid rocket boosters that provide the initial thrust needed to punch through the atmosphere. Han’s idea: engineer the lipidoid the same way. Build a central amine “head,” attach two standard alkyl epoxide “tails,” then add two acyl chloride “branched tails” as boosters.
The analogy isn’t just decorative. Functionally, those branched tails appear to do something analogous — they help the LNP breach the cell membrane more effectively, dramatically increasing how much mRNA actually gets delivered.
It’s a genuinely satisfying case of cross-domain thinking producing real results.
What They Tested It On
The team used their new lipidoids to deliver two very different things: an mRNA drug aimed at treating obesity, and gene-editing tools for genetic disease.
On the obesity side, they saw a significant increase in delivery of a hormone involved in metabolic regulation to target cells. That’s early-stage, and it’s worth being clear that this is not a drug yet — it’s a proof-of-concept that this new lipidoid design can carry obesity-related mRNA payloads more efficiently than existing formulations.
The gene-editing results are equally worth watching, though again, translation to clinic takes time.
Why This Matters
The bigger contribution here might be the manufacturing side. By streamlining the synthesis of these branched lipidoids — making it faster and more cost-effective — the Mitchell Lab has potentially lowered a significant barrier to LNP development. Better tools for building LNPs means more researchers can experiment with them, which means the pipeline for mRNA medicines — beyond vaccines — moves faster.
LNPs are already in use for one approved RNA therapy for rare disease (Onpattro, for hereditary transthyretin amyloidosis). The COVID vaccines showed the platform at scale. Papers like this one are quietly laying the groundwork for what comes next.
Sources
- Han, X. et al. (2024). Nature Communications — rdcu.be/dzF4b
- Penn Engineering News, Ian Scheffler, 26 February 2024
- Moderna & Pfizer-BioNTech LNP background — Nature Reviews Drug Discovery, Kulkarni et al. (2021)
- Onpattro (Patisiran) FDA approval — FDA.gov
- Mitchell Lab, University of Pennsylvania — mitchelllab.seas.upenn.edu
